Reduced nasal polyp size vs. placebo observed at 1 year

DUPIXENT® significantly reduced bilateral endoscopic nasal polyps score from baseline vs. placebo + INCS at week 52 (secondary endpoint)1

37% improvement at week 52 (secondary endpoint) with DUPIXENT® (n=150) (-2.24 from baseline score 6.07) vs. 3% worsening with placebo (n=153) (0.15 from baseline score 5.96) (LSM difference -2.40; 95% CI -2.77, -2.02)

28% improvement at week 24 (co-primary endpoint) with DUPIXENT® (n=295, pooled DUPIXENT® arms) (-1.71 from baseline score 6.18) vs. 2% worsening with placebo (n=153) (0.10 from baseline score 5.96) (LSM difference -1.80; 95% CI -2.10, -1.51)

Baseline

Endoscopy image of a patient’s nasal polyps at baseline.

Week 52

Endoscopy image of a patient’s nasal polyps at Week 52.

Endoscopy images adapted from actual patient images. Not representative of all patients.

Bilateral endoscopic nasal polyp score (NPS): polyps on each side of the nose were graded by central blinded readers on a categorical scale (0=no polyps; 1=small polyps in the middle meatus not reaching below the inferior border of the middle turbinate; 2=polyps reaching below the lower border of the middle turbinate; 3=large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate; 4=large polyps causing complete obstruction of the inferior nasal cavity). The total score was the sum of the right and left scores. Reduced score indicates improvement.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300229E
Last updated: 06/2023

paab logo